Major JAMA Study Shows Statins Do Not Prevent Heart Disease

Big Pharma doesn’t even blink. They’ve already got their shills out there belittling the study—so don’t expect your doctor to take you off statins just because they’re useless and dangerous.

Statins, the drug that Big Pharma has convinced leading doctors to push on nearly everyone, have finally been subjected to the study that should have been done before being approved for sale. The Journal of the American Medical Association (JAMA) reports that a large metastudy has shown that statins do not reduce death rates in people without established heart disease. Statins have no benefit for most people subjected to them.

Since 1987, we have been plagued with doctors pushing statin drugs to cure the disease of have-not-had-heart-attack-yet. From the beginning, thinking doctors and alternative practitioners have questioned the concept of treating a nonexistent disease. Basically, we were yelled down.

Bogus studies were trotted out, but the fact is that there was never a single legitimate study demonstrating any benefit from statin drugs in people who hadn’t already had heart attacks—precious little benefit for men who had suffered them, and none for women ever.

Of course, that hasn’t stopped the pressure to take statins. They supposedly reduce cholesterol, but there’s no proof of that, either.

Even more significant is that it’s never been shown that reducing cholesterol is beneficial. It’s been well-implanted in the modern medical mind—not to mention the general public’s—that cholesterol is a great evil, and that we all need to go on low-fat diets and eat statins to cut it.

It’s all nothing but a tall tale put out by Big Pharma to sell its poisons.

Big Pharma’s Spin—and Why Statins Won’t Disappear Anytime Soon

Naturally, Big Pharma isn’t going to let this setback slow them down. They’ve already trotted out Dr. Steven Nissen, who put this spin on the study:

Because mortality is low in primary-prevention patients, it is difficult to show a mortality benefit. This has been established previously. The primary benefit in this setting is reduction in nonfatal MI, which remains a worthwhile goal of therapy.

Let’s parse that statement: